BORA PHARMACEUTICALS CO., LTD.

ISIN Code: TW0006472004

Biotechnology and Medical Care

800.0 **\(\sigma \)** 59.0 High 805.0 | Low 731.0 **[**+/-/X represent Up/Down/Not compared**]**

Generated Date: 2024/05/20

Company Information

Company Name	BORA PHARMACEUTICALS CO., LTD.
Spokesman	SHIH-MIN, CHEN
Website	https://bora-corp.com/
Capital	NT 1,014,901,280
Main Business	Bora Pharmaceuticals is one of the premier pharmaceutical companies in Taiwan. We are one
	of the few companies that cover the entire pharmaceutical supply chain from research and
	development all the way to sales and distribution. Bora Pharmaceuticals has an extremely solid
	financial foundation and experienced management team, but also is continually pushing the
	boundaries of research and innovation. We have long standing partnerships with best in class
	multinationals such as Eisai, Lundbeck, Boehringer Ingelheim, and Amneal. Our internal
	business units range from a research and development, production, and in market sales and
	distribution. We also provide outsourced R&D and toll manufacturing services for domestic and
	multinational pharmaceutical companies. With Bora's US FDA certified Hsinchu plant and PIC/S
	certified Tainan Plant, we produce pharmaceuticals at the highest international standards and
	also export to over 15 counties worldwide.
Listing Date	2023/12/19
Industry	Biotechnology and Medical Care



Date	Closing Price	Trade Volume	Date	Closing Price	Trade Volume	Date	Closing Price	Trade Volume
5/17	800.0	6,719,919	5/3	746.0	1,214,496	4/18	731.0	2,412,958
5/16	741.0	1,382,466	5/2	752.0	1,428,915	4/17	754.0	2,514,782
5/15	728.0	1,979,685	4/30	765.0	1,429,673	4/16	771.0	3,545,260
5/14	710.0	1,524,555	4/29	783.0	2,443,365	4/15	795.0	5,144,195
5/13	708.0	1,819,665	4/26	752.0	1,362,418	4/12	790.0	7,328,240
5/10	713.0	2,093,370	4/25	756.0	1,559,104	4/11	817.0	5,113,445
5/9	715.0	4,598,384	4/24	757.0	2,719,260	4/10	830.0	8,159,877
5/8	743.0	1,966,494	4/23	751.0	4,612,175	4/9	758.0	3,616,563
5/7	719.0	2,560,773	4/22	718.0	2,771,903	4/8	739.0	5,472,493
5/6	742.0	2,397,460	4/19	706.0	4,383,141	4/3	761.0	7,498,571








Date	Securities	Dealers	Foreign Investors	Date	Securities	Dealers	Foreign Investors
	Investment Trust	Difference(+)/(-)	Difference(+)/(-)		Investment Trust	Difference(+)/(-)	Difference(+)/(-)
	Companies				Companies		
	Difference(+)/(-)				Difference(+)/(-)		
5/17	+176,000	+252,321	+1,489,748	4/25	+80,000	+30,653	-61,484
5/16	- 2,000	+4,176	+131,020	4/24	+102,000	-11,763	-398,949
5/15	+100,000	+48,673	+307,027	4/23	+637,000	+90,656	-390,190
5/14	- 76,000	+2,799	- 94,022	4/22	+452,000	+18,173	- 290,544
5/13	-170,000	+10,496	-228,658	4/19	+54,000	-32,588	+23,795
5/10	-135,000	-4,446	- 176,880	4/18	+1,000	- 12,400	-152,609
5/9	- 18,000	- 59,582	- 994,451	4/17	-1,000	- 27,767	-506,790
5/8	+49,000	+62,365	+509,038	4/16	-1,000	-38,651	-204,734
5/7	-100,000	-63,223	-369,914	4/15	+170,000	+9,932	+345,821
5/6	0	+25,911	- 272,722	4/12	+135,000	- 74,582	-586,978
5/3	-36,000	- 13,799	-45,990	4/11	+28,000	-105,618	+58,717
5/2	- 18,000	-4,643	-263,948	4/10	+352,000	+85,419	+1,012,800
4/30	0	- 97,878	-203,000	4/9	+146,000	+86,903	+54,702
4/29	+2,000	+91,397	+210,000	4/8	+71,000	-57,815	+87,872
4/26	+7,000	-4,670	- 210,228	4/3	+394,000	+28,301	+1,513,862





Date	Purchase on	Short Sale	Date	Purchase on	Short Sale	Date	Purchase on	Short Sale
	Margin			Margin			Margin	
5/17	- 241	+121	5/3	-105	- 17	4/18	- 57	-37
5/16	+45	+5	5/2	+45	- 4	4/17	+30	-12
5/15	-39	+6	4/30	+70	+5	4/16	+170	-15
5/14	-64	-18	4/29	- 27	+19	4/15	- 223	0
5/13	+123	- 5	4/26	+26	-11	4/12	+51	-56
5/10	-63	- 2	4/25	-34	+5	4/11	-113	-1
5/9	+86	-6	4/24	+92	-16	4/10	+328	+112
5/8	-310	+21	4/23	- 75	+32	4/9	+92	+21
5/7	+23	-14	4/22	-82	+5	4/8	- 241	-20
5/6	+110	-2	4/19	+35	- 23	4/3	+262	+40

Company Financials






2023

Quarter

	Jan	Jan-Mar		Jan-Jun		Sep	Jan-	Dec
Quarter	EPS	Income from	EPS	Income from	EPS	Income from	EPS	Income from
		continuing		continuing		continuing		continuing
		operations		operations		operations		operations
		before tax		before tax		before tax		before tax
		(Thousand)		(Thousand)		(Thousand)		(Thousand)
2024	7.07	983,540	-	-	-	-	-	-
2023	-	-	-	-	-	-	30.20	4,064,146

Monthly Revenue



Monthly	Monthly Revenue
2024/04	1,642,584,000
2024/03	752,604,000
2024/02	879,810,000
2024/01	1,225,079,000
2023/12	950,333,000
2023/11	1,126,612,000
2023/10	1,123,658,000
2023/09	1,016,198,000
2023/08	991,812,000
2023/07	1,067,848,000
2023/06	1,142,578,000



Date	PE ratio	Date	PE ratio	Date	PE ratio
5/17	29.93	5/3	24.92	4/18	24.42
5/16	27.72	5/2	25.12	4/17	25.18
5/15	27.24	4/30	25.55	4/16	25.75
5/14	26.56	4/29	26.15	4/15	26.55
5/13	23.65	4/26	25.12	4/12	26.39
5/10	23.81	4/25	25.25	4/11	27.29
5/9	23.88	4/24	25.28	4/10	27.72
5/8	24.82	4/23	25.08	4/9	25.32
5/7	24.01	4/22	23.98	4/8	24.68
5/6	24.78	4/19	23.58	4/3	25.42

Announcements

(Please refer to $\underline{\text{mops}}$ for the most updated information)

Subject	Date
▶The Company is invited to attend the Investor Conference hosted by Taishin Securities	2024/05/14 18:40:52
▶The Company's Board of Director's resolution on the Company's 2024 Q1 financial statement	2024/05/14 17:06:10
▶The Company's board of director approve the capital increase date for employee stock warrant	2024/05/14 18:33:29
convert to common share	
▶The Company's Board of Director's resolution on the cash capital increase for subsidiary Bora	2024/05/14 18:42:50
Pharmaceuticals USA Inc.,	
►Announcement on behalf of subsidiary Bora Pharmaceuticals USA Inc.'s cash capital increase for	2024/05/14 18:43:45
subsidiary Bora Pharmaceuticals Holdings, Inc.,	

Corporate Action

Year	Shareholders' meeting date	Period	Cash dividends	Stock dividends
2023	-	H2	12.00000	0.00000
2023	-	H1	0.00000	0.00000
2022	2023/06/06	H2	8.00000	3.00000
2022	-	H1	0.00000	0.00000
2021	2022/05/24	H2	3.50000	1.00000
2021	-	H1	0.00000	0.00000